Javelin Pharmaceuticals, Inc.
Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Javelin’s product candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma. Our product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. Javelin has three late stage product candidates in development: Dyloject™ (diclofenac sodium, injectable), Rylomine™ (intranasal morphine) and Ereska™ (intranasal ketamine).
Contact Details
Office Address
Javelin Pharmaceuticals, Inc.
125 CambridgePark Drive
Cambridge, MA, USA 02140
Phone: (617) 349-4500
Fax: (617) 349-4505
Executives
Chairman
Douglas G. Watson
CEO and Director
Martin J. (Marty) Driscoll